Search Results

iVascular’s Luminor DCB Evaluated in Postmarket LUMIFOLLOW Trial in Europe

February 11, 2021—iVascular announced commencement of enrollment in the prospective, multicenter, consecutive, postmarket LUMIFOLLOW trial, which is evaluating the performance of company’s Luminor drug-coated balloon (DCB) in femoropopliteal lesions of real-world patients.

iVascular’s Luminor DCB Evaluated at 1 Year in BIBLIOS and LUMIFOLLOW Studies

January 10, 2024—iVascular announced that 1-year findings from the BIBLIOS and LUMIFOLLOW studies of the company’s Luminor drug-coated balloon (DCB) were presented at PVI 2023, the Paris Vascular Insight congress held November 8-10 in Paris, France.

iVascular's luminor DCB Gains Reimbursement in France

October 4, 2019—iVascular S.L.U.

iVascular Begins FENCO Study of iCover Stent in FEVAR

February 24, 2026—iVascular announced the enrollment of the first patient in the FENCO clinical study evaluating the company’s iCover balloon-expandable polytetrafluoroethylene (ePTFE)–covered stent system in fenestrated endovascular aneurysm repair (FEVAR) for the treatment of complex abdominal aortic aneurysms.

iVascular’s Luminor DCB for Femoropopliteal Disease Evaluated in LUMIFOLLOW Registry

March 18, 2026—iVascular announced 3-year follow-up results from the LUMIFOLLOW registry, a large real-world study evaluating the safety and efficacy of the Luminor paclitaxel drug-coated balloon (DCB) in the treatment of femoropopliteal artery disease.